ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Inmagene Enrolls First Patient In Adaptive Phase 2b Clinical Trial Of Img 007
News Feed
course image
  • 07 Jul 2025
  • Admin
  • News Article

Inmagene enrolls first patient in ADAPTIVE phase 2b clinical trial of IMG-007

Overview

Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotechnology company dedicated to developing innovative and differentiated therapies for immunological and inflammatory diseases, announced the successful dosing of the first patient in its global multicenter phase 2b dose-finding study in patients with moderate-to-severe atopic dermatitis (AD).

Statement from Jonathan Wang: CEO of Inmagene

We are thrilled to have the first patient dosed in this trial, building on the encouraging clinical data observed earlier,” said Jonathan Wang, founder, chairman, and CEO of Inmagene. 

IMG-007 targets the OX40 receptor, blocking OX40–OX40L signaling in both the bloodstream and tissues, while its silenced antibody-dependent cell-mediated cytotoxicity function abolishes T-cell depleting effect, thereby potentially minimizing safety risks. In addition, its extended half-life supports the potential for convenient dosing. Together, these attributes make IMG-007 a potentially differentiated therapeutic candidate for AD patients.

About ADAPTIVE trials

• ADAPTIVE is a randomized, double-blind, placebo-controlled phase 2b trial designed to evaluate the efficacy and safety of several subcutaneous dose regimens of IMG-007 in adult participants with active moderate-to-severe AD who have had inadequate response to and/or intolerance of topical atopic dermatitis therapies. 

• The trial aims to enroll approximately 220 patients across four treatment arms (high, medium, low dose of IMG-007 and placebo) in a 1:1:1:1 ratio.

  • Period 1: A 20-week randomized double-blind, placebo-controlled treatment period.
  • Period 2: A subsequent 32-week double-blind active treatment period during which all participants, including those initially randomized to placebo, will receive active treatment.

The Outcomes 

• The primary endpoint of the study is mean percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 20. 

• Key secondary endpoints include mean percentage change from baseline in EASI score at Week 16, as well as proportion of patients achieving EASI-75 (= 75% improvement in EASI score) and Investigator's Global Assessment (IGA) score of 0 or 1 (clear or almost clear) at week 16 and 20, respectively.

About The ADAPTIVE phase 2b trial

• The ADAPTIVE phase 2b trial evaluates multiple dose regimens of IMG-007 in patients with moderate-to-severe atopic dermatitis. 

• Topline data is expected in the fourth quarter of 2026. 

• This dose-finding study is designed to generate data that will guide the design and selection of optimal dosing regimens for future phase 3 clinical trials.

About the monoclonal antibody: IMG-007

• IMG-007 is a humanized, subcutaneously administered, non-depleting IgG1 monoclonal antibody targeting OX40. 

• It features a silenced antibody-dependent cell-mediated cytotoxicity function and an extended half-life. 

• The OX40–OX40L signaling plays a key role in T cell activation, expansion, and survival, making it an attractive target for the treatment of immunological and inflammatory diseases. 

• In nonclinical studies, IMG-007 demonstrated potent inhibition of OX40–OX40L signaling. 

• Its subcutaneous formulation has shown a half-life of 34.7 days at the anticipated therapeutic dose level, supporting the potential for infrequent and convenient dosing. 

• In a phase 2a trial in patients with moderate-to-severe atopic dermatitis, IMG-007 exhibited sustained clinical activity and was well tolerated, with no reported cases of pyrexia or chills. IMG-007 was originally discovered by Hutchmed.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form